

INDEX TO VOLUME 90

Editorials, Letters to the Editor, Case Reports and Short Reports are indicated by (E), (L), (CR) and (SR) after the page numbers, respectively.

- Abba AA 631-4 (CR)
 Abbasciano V 183-4 (L)
 Abe M 329-32
 Adenocarcinoma of lung 333-7
 Adenosine deaminase in tuberculous pleural effusion 95-98
 Adult respiratory distress syndrome
 from *Chlamydia pneumoniae* 311-13 (CR)
 surfactant and 251-70
 Aguilar X 231-3
 Airway calibre effect on bronchial responsiveness in COPD 323-8
 Al-Majed SA 211-14
 Albumin increases in BAL fluid following smoking cessation 523-9
 Alderice J 57-59 (CR)
 Allergen avoidance measures 441-5
 Alpha-1 antitrypsin
 deficiency, patient-administered sequential spirometry in 131-8
 replacement therapy 5-23
 Alvarez D 61-62 (CR)
 Alveolar macrophage
 activity, surfactant and 251-70
 hydrolytic enzyme, in diffuse pulmonary interstitial disease 159-66
 Alveolar proteinosis, surfactant and 251-70
 Alveolar type II cells, surfactants and 251-70
 Ambrosino N 317-22
 Ambulatory asthma care 447-52
 Amiodarone
 -induced bronchiolitis obliterans organizing pneumonia 167-9 (CR)
 pneumonitis 119 (L)
 Anagnostakis J 201-4
 Antibodies for diagnosing malignant mesothelioma 191-9
 Anti-leukotriene intervention in asthma 575-86
 Apnoea, temporary obstructive syndrome from cryptococcal encephalitis 571-4 (CR)
 Apostolakis J 201-4
 Arm muscle groups training for pulmonary disease 317-22
 Aspirin-induced asthma, menthol and 247 (L)
 Asthma
 allergen avoidance measures 441-5
 anti-leukotriene intervention 575-86
 in athletes 1-3 (E)
 beclomethasone effect on serum markers of collagen metabolism in postmenopausal women 339-42
 breathing pattern variability during bronchial challenge 271-7
 care comparisons 539-45
 compared to chronic bronchitis 187-90
 comparing male and female presentation to emergency department 485-9
 deaths 454-7
 electronic diary card spirometer assessment 619-22
 exercise-induced bronchoconstriction 145-51
 factors affecting oxygen saturation during methacholine challenge 473-7
 fluticasone propionate compared to beclomethasone dipropionate 609-17
 HLA antigens in Greeks 201-4
 hyperventilation during bronchial challenge 271-7
 long-term use of nebulizers 561-6
 menthol and aspirin-induced 247 (L)
 prevalence in cross-country skiers 99-105
 psychosocial factors 454-7
 risk factors in children 623-30
 severity and outcome measures 447-52
 therapy trends 5-23
 Athletes, obstructive symptoms in 1-3 (E)
 Atopy, eosinophil peroxidase marker 39-46
 Autoantibody status related to lung involvement in system sclerosis 223-30
 Awadh N 485-9
 B72.3 for diagnosing malignant mesothelioma 191-9
 Backer V 623-30
 Badgers, bovine TB in 371-3 (L)
 Bagei Ceyhan B 215-21
 Bailey CM 567-9 (CR)
 BAL
 cytology in pulmonary fibrosis with neurofibromatosis 465-7 (CR)
 fluid, cholesterol crystals in pulmonary fibrosis 361-3 (SR)
 expression of phospholipase A² in lower respiratory tract in smokers 479-83
 increases in albumin and hyaluronan following smoking cessation 523-9
 Baloti H 205-9
 Baraff LJ 593-9
 Barrios MN 159-66
 Bauer K 609-17
 Bear MB 587-92
 Beclomethasone
 dipropionate, compared to fluticasone propionate in asthma 609-17
 effect on serum markers of collagen metabolism in postmenopausal asthmatic women 339-42
 Ben-Dor D 167-9 (CR)
 Bener A 89-94
 Bennett LS 357-9 (SR)
 Benson MK 119 (L)
 BerEp4 for diagnosing malignant mesothelioma 191-9
 Berkman N 121-2 (L), 307-9 (CR)
 Bernstein A 561-6
 Beta-adrenoceptor agonist therapy for COPD 513-22
 Bin-Othman SA 89-94
 Bird CM 107-9 (CR)
 Biv J 307-9
 Bjerke T 271-7
 Bjerner L 1-3 (E), 99-105
 Bjornsson E 39-46
 Bjortuft O 553-9
 Blaschke E 523-9
 Blood gases, capillary, time delay effect on measurement 107-9 (SR)
 Boe J 553-9
 Bogaard JM 619-22
 Boman G 39-46
 Bonifazi F 609-17
 Book Reviews
 ABC of resuscitation 370
 Airways smooth muscle: peptide receptors, ion channels and signal transduction 369
 Asthma 117
 Biopsy interpretation of the lung 186-1
 Chronic obstructive pulmonary disease 369-70
 Clinical ecology of cystic fibrosis 179
 Drugs and the lung 179-80
 Effects of nicotine on biological systems II 243
 High altitude medicine and physiology 117-18
 Methylxanthines and phosphodiesterase inhibitors in the treatment of airways disease 244
 Minimally invasive techniques in thoracic medicine and surgery 245
 Practical management of asthma 639

- Textbook of respiratory medicine* 243-4
Tuberculosis 244-5
 Bouros D 311-13 (CR)
 Bousquet J 79-85, 187-90
 Bovine TB
 in badgers 371-3 (L)
 in cattle and wildlife 184 (L)
 Brackel HJL 619-22
 Brain natriuretic peptide in pulmonary hypertension 247-9 (L)
 Breathing
 control techniques for pulmonary disease 317-22
 pattern variability during bronchial challenges in asthma 271-7
 Breuer R 307-9
 Bronchial atresia, recurrent spontaneous pneumothorax and 307-9
 Bronchial biopsies in asthma and chronic bronchitis, cytokine patterns 79-85
 Bronchial challenge
 in asthma, breathing pattern variability 271-7
 factors affecting oxygen saturation 473-7
 Bronchial hyper-responsiveness, eosinophil peroxidase marker 39-46
 Bronchial multiple pulmonary chondrohamartomas, literature review 111-14 (SR)
 Bronchial obstruction, hyperventilation in asthma and 271-7
 Bronchial responsiveness in COPD, effect of airway calibre and pulmonary emphysema 323-8
 Bronchiectasis and Feltz's syndrome 249 (L)
 Bronchiolitis obliterans
 organizing pneumonia, amiodarone-induced 167-9 (CR)
 syndrome following lung transplant for COPD 553-9
 Bronchitis
 chronic, compared to asthma 187-90
 cytokine patterns in bronchial biopsies 79-85
 factors affecting oxygen saturation during methacholine challenge 473-7
 Bronchoconstriction in asthma, exercise-induced 145-51
 Bronchoscope
 cleaning 373 (L)
 contamination 63-67 (E)
 Bronchoscopy, informed consent 183-4 (L)
 Bucknall CE 447-52
 Bullock GR 79-85
 Burgut R 25-33
 Burnett H 315-16 (L)
 Buysse B 571-4 (CR)

 Campbell AM 79-85
 Campbell CA 547-51
 Campbell IA 47-51, 353-6
 Capewell S 333-7
 Capsaicin cough sensitivity during respiratory infection 271-7
 Caputi M 497-9 (SR)
 Carcinoembryonic antigen for diagnosing malignant mesothelioma 191-9
 Carroll KB 547-51
 Carson J 57-59 (CR)
 Cauda R 531-7
 Cazzola M 497-9 (SR)
 Celikel T 215-21
 Cell signalling pathways, surfactant and 251-70
 Chanez P 79-85, 187-90
 Chest
 physical therapy for pulmonary disease 317-22
 X-rays, classification of pulmonary lesions 349-52
 Children
 asthma risk factors 623-30
 Hering-Breuer reflex during ventilation 463-6
 peak flow monitoring 459-61
 premature, inhaled nedocromil sodium for 467-71
 Chiyotani A 247 (L) *Chlamydia pneumoniae* causing ARDS 311-13 (CR)
 Cholesterol crystals in BAL fluid in pulmonary fibrosis 361-3 (SR)
 Chondrohamartomas, pulmonary, in respiratory tract, literature review 111-14 (SR)
 Chong I-W 343-8
 Christacopoulou J 95-98
 Christensen I 271-7
 Chronic obstructive pulmonary disease (COPD)
 effect of airway calibre and pulmonary emphysema on bronchial responsiveness in 323-8
 long-term use of nebulizers 561-6
 outpatient management 357-9 (SR)
 pulmonary function and bronchiolitis obliterans syndrome following lung transplant 553-9
 respiratory muscle pharmacotherapy 513-22
 salmeterol and/or ipratropium 497-9 (SR)
 Chu S 485-9
 Cirrhosis of liver, chylothorax in 61-62 (CR)
 Claverley PMA 123-5 (E)
 Clenbuterol therapy for COPD 513-22
 Clough JB 459-61
 Cocaine-induced pulmonary hypertension 171-4 (CR)
 Collagen metabolism serum markers in postmenopausal asthmatic women, effect of beclomethasone 339-42
 Collazos J 171-4 (CR)
 Conant EF 223-30
 Connolly MJ 473-7
 Corticosteroid injection for eosinophilic pleural effusion 501-3 (CR)
 Costabel U 465-7 (CR)
 Cough sensitivity to capsaicin, respiratory infection and 271-7
 Cryptococcal encephalitis, temporary obstructive apnoea syndrome in 571-4 (CR)
 Cryptogenic fibrosing alveolitis, treatment vs prognosis 127-30
 Cryptogenic organizing pneumonia in Sweet's syndrome 57-59 (CR)
 Cystic fibrosis
 lung collapse and nerve paralysis 567-9 (CR)
 treatments 5-23
 venous access devices 353-6
 Cystic thymoma diagnosis 635-7 (CR)
 Cytokeratin for diagnosing malignant mesothelioma 191-9
 Cytokine
 patterns in bronchial biopsies in asthma and chronic bronchitis 79-85
 surfactants and 251-70

 d'A Semple P 120-1 (L)
 Dahl R 271-7
 Daifuku R 587-92
 Death from TB in Edinburgh 119-20 (L)
 Deep vein thrombosis in SLE and varicella 239-41 (CR)
 Deiraniya AK 547-51
 Dejmek A 191-9
 Dekhuijzen PNR 513-22
 Demedts M 571-4 (CR)
 Dev D 333-7
 Dimakou K 53-55 (CR), 95-98
 Dirksen A 131-8, 349-52, 623-30
 DNase, recombinant human, for cystic fibrosis 5-23
 Dominguez H 111-14 (SR)
 Drug-induced pulmonary disease, surfactant and 251-70
 Durham SR 441-5

 Education programmes for self-help care for pulmonary disease 317-22
 Egan JJ 127-30, 547-51
 Eklund A 523-9
 Elborn JS 353-6
 Empey DW 567-9 (CR)
 Emphysema-like changes in spontaneous pneumothorax 491-6
 Emphysematous bulla, spontaneous closure 120-1 (L)
 Enander I 39-46
 Encephalitis, cryptococcal, temporary obstructive apnoea syndrome in 571-4 (CR)
 Eosinophil
 degranulation in pneumonia 505-9 (CR)

- peroxidase marker of atopy and bronchial hyper-responsiveness 39-46
secretion of IL-4 271-7
Eosinophilic pleural effusion, corticosteroid injection for 501-3 (CR)
Epithelial membrane antigen for diagnosing malignant mesothelioma 191-9
Exercise, hyperventilation during 145-51
Extracellular matrix patterns in malignant mesothelioma 191-9
- Faurschou P 349-52
Feltz's syndrome, bronchiectasis and 249 (L)
Fernandez A 171-4 (CR)
Fessas PH 201-4
Fibrosing alveolitis, cryptogenic, treatment vs prognosis 127-30
Fireman E 361-3 (SR)
Fish JE 223-30
Fitzgerald M 485-9
Fiz JA 231-3
Fjeld J 553-9
Fluticasone propionate compared to beclomethasone dipropionate in asthma 609-17
Foglio K 317-22
Folgering H 513-22
Forlund L 131-8
Fotheringham N 587-92
Fujimura M 115-16 (SR), 501-3 (CR)
Fujino S 329-32
Fujita J 35-38, 153-7
Fuller RW 271-7
- Gaga M 53-55 (CR), 95-98
Gaustadnes M 271-7
Geiran OR 553-9
Gene therapy for cystic fibrosis 5-23
Georgoulas V 201-4
Gheuens E 505-9 (CR)
Giffin F 463-6
Gioulekas D 205-9
Godschalk I 619-22
Golding RP 491-6
Goldman JM 119-20 (L)
Goltzman B 167-9 (CR)
Gonzalez-Buitrago JM 159-66
Greenough A 463-6
Grief J 361-3 (SR)
Growth hormone therapy for COPD 513-22
Grunfeld A 485-9
Gustafsson PM 271-7
Gysbrechts C 571-4 (CR)
- Haak T 601-8
Haemosiderin-laden macrophages following heart transplantation 547-51
Hakansson L 39-46
Hamm H 251-70
Hancox M 184 (L), 71-3 (L)
Hansen KK 131-8
Harada M 153-7
Hargreaves MR 119 (L)
Hariri J 111-14 (SR)
Harris TAJ 609-17
Harrison BDW 539-45
Harvey J 63-67 (E)
Harvey JS 353-6
Hasegawa S 635-7 (CR)
Hasleton PS 547-51
Heart
 and lung transplants 5-23
 transplantation, pulmonary interstitial fibrosis and
 haemosiderin-laden macrophages following 547-51
Hering-Breuer reflex in ventilated children 463-6
Herrala J 339-42
Hesse B 623-30
- Heusser C 79-85
Hirose J-I 115-16 (SR)
Histamine challenge in asthma, breathing pattern variability 271-7
HIV infection, staphylococcal pneumonia predictors 531-7
Hiwada K 329-32
HLA antigens and asthma in Greeks 201-4
Hohlfield J 251-70
Hojo S 35-38, 153-7
Hormonal changes in patients with acute hypoxaemic respiratory failure 601-8
Hospital treatment of asthma 447-52
House dust mite avoidance measures 441-5
Huang D-F 239-41 (CR)
Huang M-S 343-8
Humphreys H 87-88
Hurone T 115-16 (SR)
Hwang J-J 343-8
Hyaluronan
 increases in BAL fluid following smoking cessation 523-9
 in malignant mesothelioma 191-9
Hydrolytic enzyme of alveolar macrophage in diffuse pulmonary interstitial disease 159-66
Hydrothorax, spontaneous neutrocytic hepatic, without ascites 631-4 (CR)
Hypersensitivity pneumonitis, surfactant and 251-70
Hyperventilation
 during bronchial challenge in asthma 271-7
 during exercise 145-51
- Idiopathic pulmonary fibrosis, surfactant and 251-70
Ikeda A 323-8
Ind PW 575-86
Inflammatory reactions, role of IL-8 215-21
Informed consent for bronchoscopy 183-4 (L)
Inhalation devices, novel 5-23
Inhalers, choosing 69-77
Interleukin-1 in tuberculous pleural effusion 95-98
Interleukin-4 secretion by human blood eosinophils 271-7
Interleukin-6 receptor levels in pleural effusions 329-32
Interleukin-8 in pleural effusion 215-21
Ipratropium and/or salmeterol in COPD 497-9 (SR)
Irradiation pneumonitis, surfactant and 251-70
Ishida O 329-32
Ishikawa H 635-7 (CR)
Ishiura Y 501-3 (CR)
Izumi T 323-8
- Janson C 39-46
Janssen JP 491-6
Jarnvig I-L 349-52
Jimenez A 159-66
Jimenez S 223-30
Johansen B 553-9
Johnson PH 87-88
Jokaji H 501-3 (CR)
Jordanoglou J 53-55 (CR), 95-98
Jorens PG 505-9 (CR)
Jungmann E 601-8
- Kamaroulas D 201-4
Kamma H 635-7 (CR)
Kane GC 223-30
Kano S 171-4 (CR)
Kara K 25-33
Kawane H 247 (L)
Kendrick AH 315 (L)
Keratins for diagnosing malignant mesothelioma 191-9
Kerr KM 373 (L)
Kinnula VL 145-51
Kitamura S 171-4 (CR)
Kivity S 361-3 (SR)
Koc; M 215-21
Kocabas A 25-33
Kohno N 329-32

- Kok-Jensen A 131-8
 Konno K 247 (L)
 Konstantopoulos K 201-4
 Koyama H 323-8
 Kramer MR 121-2 (L)
 Kroegel C 251-70
 Kullmer T 601-8
- Laajam MA 631-4 (CR)
 Lai C-S 343-8
 Lai R-S 139-43
 Lamb D 333-7
 Langaker KE 609-17
 Larsson L 1-3 (E), 99-105
 Latsi P 53-55 (CR), 95-98
 Lee SS-J 139-43
 Leg exercise training for pulmonary disease 317-22
 Leukotriene intervention therapy in asthma 575-86
 LeuM1 for diagnosing malignant mesothelioma 191-9
 Liippo K 339-42
 Lin B-C 239-41 (CR)
 Lin C-C 139-43
 Lin H-C 343-8
 Lin M-S 343-8
 Liver cirrhosis, chylothorax in 61-62 (CR)
 London D 167-9 (CR)
 Lorentzen KA 609-17
 Lu J-Y 139-43
 Lucia MB 531-7
- Lung
 adenocarcinoma 333-7
 collapse and nerve paralysis in cystic fibrosis 567-9 (CR)
 cyst, traumatic 115-16 (SR)
 disease, new treatments 5-23
 function, surfactant and 251-70
 involvement in systemic sclerosis 223-30
 parenchyma, multiple pulmonary chondrohamartomas, literature review 111-14 (SR)
 transplants 5-23
 for COPD, pulmonary function and bronchiolitis obliterans syndrome 553-9
 surfactant and 251-70
 Lymphangioliomyomatosis, pulmonary, and tuberous sclerosis 121-2 (L)
 Lymphocyte activity, surfactant and 251-70
- MacFarlane JT 87-88
 Macrophages, surfactant and 251-70
 Madsen F 131-8
 Mahmoud K 249 (L)
 Martin N 547-51
 Martin T 159-66
 Martinez E 171-4 (CR)
 Matera MGH 497-9 (SR)
 Matsuda T 115-16 (SR), 501-3 (CR)
 Mayo J 171-4 (CR)
 Meier-Sydow J 601-8
 Menthol and aspirin-induced asthma 247 (L)
 Mesothelioma, malignant, diagnostic accuracy 191-9
 Methacholine challenge
 in asthma, breathing pattern variability 271-7
 factors affecting oxygen saturation 473-7
 Methylxanthine therapy for COPD 513-22
 Meyer FJ 465-7 (CR)
 Michel FB 187-90
 Michiels E 571-4 (CR)
 Millar EA 120-1 (L)
 Miller MR 371 (L)
 Milman N 349-52
 Milroy R 315 (L)
 Minami S 501-3 (CR)
 Mishima M 323-8
 Miyawaki H 35-38, 153-7
 Mizuhashi K 115-16 (SR)
- Morbidity, time to resolution endpoint in community-acquired pneumonia 587-92
 Morbitzer D 601-8
 Morera J 231-3
 Morgan MDL 97-99 (CR)
 Mortality in asthma 454-7
 Movahhed R 587-92
 Mower WR 593-9
 Mueller R 79-85 *Mycobacterium avium* infection, pulmonary alveolar proteinosis in 641 (L)
- Naik S 463-6
 Nakamura N 501-3 (CR)
 Nebulization optimization 315-16 (L)
 Nebulizer
 choosing 69-77
 long-term use study 561-6
 Nedocromil sodium, inhaled, for premature children 467-71
 Negayama K 35-38
 Nelson S 587-92
 Nerve paralysis and lung collapse in cystic fibrosis 567-9 (CR)
 Nicklin EL 593-9
 Nicotine, transdermal, in patients with smoking-related diseases 47-51
 Nielsen LP 271-7
 Nielsen NH 131-8
 Nielsen S 271-7
 Niggeman B 371 (L)
 Nishimura K 323-8
 Nissen F 349-52
 Noda Y 115-16 (SR)
 Noro M 635-7 (CR)
 Nosocomial pneumonia in immunocompromised patients 35-38
- O'Connell F 271-7
 O'Driscoll BR 561-6
 Obstructive lung disease, surfactant and surfactant and 251-70
 see also chronic obstructive pulmonary disease
 Occupational therapy for pulmonary disease 317-22
 Ogawa M 479-83
 Ohtsuka M 635-7 (CR)
 Oren S 167-9 (CR)
 Orphanidou D 53-55 (CR), 95-98
 Ortona L 531-7
 Oxygen saturation during methacholine challenge 473-7
 Özgün S 215-21
 Özgür G 25-33
- Panagou P 311-13 (CR)
 Panbronchiolitis in rheumatoid arthritis 175-7 (CR)
 Pandalos J 95-98
 Papakosta D 205-9
 Patient screening, pulse oximetry compared to respiratory rate 593-9
 Peak flow
 meters performance after prolonged use 371 (L)
 monitoring in children 459-61
 Pearson MG 539-45
 Pearson SB 119-20 (L)
 Pedersen S 69-77
 Perez-Arellano JL 159-66
 Peters JCK 619-22
 Phospholipase A₂ expression in lower respiratory tract of smokers 479-83
 Pless S 111-14 (SR)
 Pleural effusion
 corticosteroid injection for 501-3 (CR)
 IL-6 receptor levels 329-32
 IL-8 in 215-21
 tuberculous, paradoxical response to chemotherapy 211-14
 TNF, IL-1 and adenosine deaminase in 95-98 *Pneumocystis carinii* sequence detection in serum 153-7
 Pneumocytes, surfactant and 251-70

- Pneumonia
 bronchiolitis obliterans organizing, amiodarone-induced 167-9 (CR)
 community-acquired, time to resolution of morbidity 587-92
 cryptogenic organizing, in Sweet's syndrome 57-59 (CR)
 eosinophilic, eosinophil degranulation 505-9 (CR)
 in immunocompromised patients 35-38
 staphylococcal, predictors in HIV infection 531-7
 surfactant and 251-70
- Pneumonitis
 amiodarone 119 (L)
 surfactant and 251-70
- Pneumothorax
 recurrent spontaneous, with bronchial atresia 307-9
 spontaneous, pulmonary function 491-6
 pulmonary oedema following 235-8 (CR)
- Polkey M 119 (L)
 Polosa R 121 (L)
 Pose A 61-62 (CR)
 Postmus PE 491-6
 Poulsen LK 271-7
 Premature children, inhaled nedocromil sodium for 467-71
 Prescott RJ 47-51
 Pride NB 271-7
 Proteinosis, surfactant and 251-70
 Psychosocial factors in asthma 454-7
 Psychosocial support for pulmonary disease 317-22
 Pulmonary alveolar proteinosis in disseminated *Mycobacterium avium* infection 641 (L)
 Pulmonary chondromatosis in respiratory tract, literature review 111-14 (SR)
 Pulmonary complications, postoperative, preoperative spirometry for prediction 25-33
 Pulmonary embolism in SLE and varicella 239-41 (CR)
 Pulmonary emphysema effect on bronchial responsiveness in COPD 323-8
 Pulmonary fibrosis
 cholesterol crystals in BAL fluid 361-3 (SR)
 surfactant and 251-70
 treatments 5-23
 with neurofibromatosis, BAL cytology 465-7 (CR)
 Pulmonary function in spontaneous pneumothorax 491-6
 Pulmonary haemorrhage in SLE and varicella 239-41 (CR)
 Pulmonary hypertension
 acute reversible, following cocaine 171-4 (CR)
 brain natriuretic peptide in 247-9 (L)
 Pulmonary interstitial disease, diffuse, hydrolytic enzyme of alveolar macrophage 159-66
 Pulmonary interstitial fibrosis and haemosiderin-laden macrophages following heart transplantation 547-51
 Pulmonary lesions classification on chest X-rays 349-52
 Pulmonary lymphangioleiomyomatosis and tuberous sclerosis 121-2 (L)
 Pulmonary nodule diagnosis, tuberculous, lung biopsy value in 139-43
 Pulmonary oedema following pneumothorax 235-8 (CR)
 Pulmonary rehabilitation, selection criteria 317-22
 Pulse oximetry compared to respiratory rate in patient screening 593-9
 Puolijoki H 339-42
- Quality of life assessment 641 (L)
 Quantrill SJ 249 (L)
- Rahman AN 547-51
 Rasidakis A 53-55 (CR), 95-98
 Reactive oxygen-derived species scavenger therapy for COPD 513-22
 Reid PT 57-59 (CR)
 Reimert CM 271-7
 Renwick DS 473-7
 Respiratory allergy in cross-country skiers 99-105
 Respiratory failure, acute hypoxaemic, hormonal changes in 601-8
 Respiratory infection, capsaicin cough sensitivity and 271-7
- Respiratory muscle
 pharmacotherapy in COPD 513-22
 training for pulmonary disease 317-22
 Respiratory papillomatosis with malignant transformation 53-55 (CR)
 Respiratory pressures circadian rhythms 231-3
 Respiratory rate compared to pulse oximetry in patient screening 593-9
 Respiratory symptoms in premature children, inhaled nedocromil sodium for 467-71
 Respiratory tract
 lower, phospholipase A² expression 479-83
 viral infection, treatments 5-23
- Revill SM 97-99 (CR)
 Rheumatoid arthritis, panbronchiolitis in 175-7 (CR)
 Richart C 231-3
 Ringbaek T 641 (L)
 Risteli J 339-42
 Risteli L 339-42
 Rogers DF 5-23
 Rosenman J 235-8 (CR)
 Rudiger N 271-7
 Ryland I 539-45
- Sachs C 593-9
 Safa P 593-9
 Saitoh K 171-4 (CR)
 Sakai A 247 (L)
 Sakai N 323-8
 Salbutamol Rotahaler vs terbutaline Turbuhaler in asthma 205-9
 Salmeterol and/or ipratropium for COPD 497-9 (SR)
 Sanchez ML 159-66
 Sankaran R 333-7
 Sarcoidosis, surfactant and 251-70
 Sartori S 183-4 (L)
 Satoh H 635-7 (CR)
 Schiøtz PO 271-7
 Schnabel R 465-7 (CR)
 Schramel FMNH 491-6
 Shale DJ 353-6
 Shinagawa S 115-16 (SR)
 Shiner RJ 235-8 (CR)
 Shirakusa T 479-83
 Simansky DA 235-8 (CR)
 Simpson K 485-9
 Sinnamon DG 57-59 (CR)
 Skin involvement related to lung involvement in systemic sclerosis 223-30
 Sköld CM 523-9
 Skovlund E 553-9
 Smith EC 315 (L)
 Smoking
 cessation 123-5 (E)
 increases in albumin and hyaluronan in BAL fluid 523-9
 with transdermal nicotine 47-51
 factors affecting oxygen saturation during methacholine challenge 473-7
 phospholipase A² expression in lower respiratory tract 479-83
 Sonmez H 25-33
 Sovijarvi ARA 145-51
 Spacers 69-77
 Spirn PW 223-30
 Spirometer, electronic diary card assessment in asthma 619-22
 Spirometry
 in non-smoking Chinese women 343-8
 patient-administered sequential, in α_1 -antitrypsin deficiency 131-8
 preoperative, for prediction of pulmonary complications 25-33
 Spitzer S 361-3 (SR)
 Sputum microbiology in general practice 87-88
 Squamous cell carcinoma from respiratory papillomatosis transformation 53-55 (CR)
Staphylococcus aureus pneumonia predictors in HIV infection 531-7

- Stenotrophomonas maltophilia* pneumonia, clinical features in immunocompromised patients 35-38
- Steroid therapy for COPD 513-22
- Strömberg NOT 271-7, 271-7
- Studham JM 271-7
- Sudlow MF 333-7
- Sue-Chu M 99-105
- Sugiyama Y 171-4 (CR)
- Suguri S 153-7
- Surfactant 251-70
- Sweet's syndrome, cryptogenic organizing pneumonia in 57-59 (CR)
- Swinburn CR 357-9 (SR)
- Systemic lupus erythematosus and varicella, pulmonary problems and DVT in 239-41 (CR)
- Systemic sclerosis, lung involvement 223-30
- Taconelli E 531-7
- Takahara J 35-38, 153-7
- Takemura H 247 (L)
- Tamaoki J 247 (L)
- Teale C 119-20 (L)
- Terbutaline Turbohaler vs salbutamol Rotahaler in asthma 205-9
- Teschler H 465-7 (CR)
- Tetley TD 5-23
- Texido A 231-3
- Thomas PS 247-9 (L)
- Thomas VE 271-7
- Thompson RD 567-9 (CR)
- Thymoma, cystic, diagnosis 635-7 (CR)
- Ting Y-M 139-43
- Tjeder-Burton SM 47-51
- Topilsky M 361-3 (SR)
- Toumbis M 53-55 (CR), 95-98, 201-4
- Trachea, multiple pulmonary chondrohamartomas, literature review 111-14 (SR)
- Transbronchial lung biopsy value in tuberculous pulmonary nodule diagnosis 139-43
- Trevisani L 183-4 (L)
- Tsai C-Y 239-41 (CR)
- Tsai M-S 343-8
- Tsai Y-Y 239-41 (CR)
- Tsipra S 311-13 (CR)
- Tuberculin reactivity factors in children from UAE 89-94
- Tuberculosis
- bovine, in badgers 371-3 (L)
 - in cattle and wildlife 184 (L)
 - mortality in Edinburgh 119-20 (L)
 - treatments 5-23
- Tuberculous pleural effusion
- paradoxical response to chemotherapy 211-14
 - TNF, IL-1 and adenosine deaminase in 95-98
- Tuberculous pulmonary nodule diagnosis, lung biopsy value in 139-43
- Tuberous sclerosis and pulmonary lymphangioleiomyomatosis 121 (L)
- Tumbarello M 531-7
- Tumour necrosis factor in tuberculous pleural effusion 95-98
- Turkot S 167-9 (CR)
- Uduman S 89-94
- Ulrik CS 131-8, 623-30
- Valdes L 61-62 (CR)
- Valle JM 61-62 (CR)
- Vamvalis C 205-9
- Van Alsenov L 505-9 (CR)
- Van der Heijden HFM 513-22
- Van Helmond JLM 609-17
- Van Herwaarden CLA 513-22 van Keimpema ARJ 491-6
- Van Meerbeek JP 505-9 (CR)
- Van Overveld FJ 505-9 (CR)
- Vara DD 97-99 (CR)
- Varga J 223-30
- Varicella and SLE, pulmonary problems and DVT in 239-41 (CR)
- Venge P 39-46
- Venous access devices in cystic fibrosis 353-6
- Verhoef G 571-4 (CR)
- Vermeire PA 505-9 (CR)
- Vignola AM 187-90
- Vilalta P 231-3
- Vimentin for diagnosing malignant mesothelioma 191-9
- Viskum K 131-8
- Von Recklinghausen's disease with pulmonary fibrosis, BAL cytology 465-7 (CR)
- Vordoyanni P 205-9
- Wang H-C 139-43
- Wang S-R 239-41 (CR)
- Weiler Z 167-9 (CR)
- Winkelman BR 601-8
- Woodcock AA 127-30, 547-51
- Wright peak flow meters performance after prolonged use 371 (L)
- Xu G 35-38
- Yalçin M 215-21
- Yamadori I 35-38
- Yamaji Y 35-38, 153-7
- Yamashita J-I 479-83
- Yang A-H 239-41 (CR)
- Yates M 63-67 (E)
- Yellin A 235-8 (CR)
- Yng B 353-6
- Yokoyama A 329-32
- Yonan N 547-51
- Zargar SA 631-4 (CR)
- Zervas J 201-4

